SAGE•benzinga•
Sage Therapeutics Announced Topline Results From The Phase 2 DIMENSION Study Of dalzanemdor (SAGE-718) In Participants With Cognitive Impairment (CI) Associated With Huntington's Disease (HD)
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 20, 2024 by benzinga